The laboratory of Dr. Milena Kordalewska is seeking an experienced and highly motivated Senior Research Specialist, Antifungal Drug Development to take a leading experimental role in our translational research programs focused on the development of novel antifungal drugs. Our lab is at the forefront of investigating emerging and drug-resistant fungal pathogens, and this senior position offers a unique opportunity to significantly contribute to a collaborative, mission-driven team. The successful candidate will be instrumental in driving preclinical drug discovery initiatives, with the ultimate goal of addressing a significant global health threat and improving patient outcomes.
Key responsibilities will include:
- Independently design, execute, and troubleshoot complex experiments that are foundational to our drug development pipeline.
- Lead the implementation of comprehensive in vitro evaluations to determine the potency and spectrum of activity of novel antifungal compounds.
- Develop and optimize a variety of molecular biology assays to elucidate mechanisms of drug action and resistance.
- Optimize and execute in vivo drug efficacy models in rodents to assess the therapeutic potential of lead candidates.
We are seeking a candidate with substantial experience in microbiology, pharmacology, or a related field, coupled with a proven track record in translational research. The following lab experience and skills are highly desirable:
- Extensive hands-on expertise in cultures of microbial pathogens, particularly yeasts and filamentous fungi.
- Demonstrated proficiency in a wide range of drug susceptibility testing methodologies.
- Proven experience with in vitro and in vivo biofilm models.
- Strong background in molecular biology techniques, e.g., PCR, nucleic acid isolation.
- Experience with animal models of infectious diseases, including drug administration, tissue collection, and data analysis.
The Center for Discovery and Innovation- CDI was established by Hackensack Meridian Health (HMH) as an academic basic and translational research enterprise to rapidly translate science innovation to the clinic and to improve outcomes for patients with cancer, infectious diseases, autoimmune disease and other acute and chronic diseases. The CDI has grown rapidly since its origins in 2019, and now has 39 labs, 200+ scientists and allied personnel supported by 78 NIH and DoD grants and more than 87 other grants and contracts. Areas of expertise include genomics, epigenetics, drug resistance, stem cell biology, drug discovery, diagnostics and biomarker development, rheumatology and pharmacology.
